Instil Bio, Inc. Lease, Cost
Instil Bio, Inc. (TIL) reported Lease, Cost of $231.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-13
- Instil Bio, Inc. lease, cost for the quarter ending 2026-06-30 was $231.00K, a 73.11% decline year-over-year.
- Instil Bio, Inc. lease, cost for the quarter ending 2026-03-31 was $367.00K, a 37.48% decline year-over-year.
- Instil Bio, Inc. lease, cost for the quarter ending 2025-12-31 was $499.00K, a 34.86% increase year-over-year.
- Instil Bio, Inc. lease, cost for the quarter ending 2025-09-30 was $314.00K, a 30.99% decline year-over-year.
- Instil Bio, Inc. lease, cost for fiscal 2025 was $2.26M, a 6.76% increase from fiscal 2024.
- Instil Bio, Inc. lease, cost for fiscal 2024 was $2.12M, a 36.93% decline from fiscal 2023.
- Instil Bio, Inc. lease, cost for fiscal 2023 was $3.35M, a 52.77% decline from fiscal 2022.
- Instil Bio, Inc. lease, cost for fiscal 2022 was $7.10M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $231.00K 10-Q · filed 2026-08-13 | $599.00K 10-Q · filed 2026-08-13 | $1.10M derived: sum of 3 quarters · filed 2026-08-13 | $1.41M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $367.00K 10-Q · filed 2026-05-15 | $866.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.18M derived: sum of 3 quarters · filed 2026-05-15 | $2.04M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $813.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.67M derived: sum of 3 quarters · filed 2026-08-13 | $2.26M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $314.00K 10-Q · filed 2025-11-13 | $1.17M derived: sum of 2 quarters · filed 2026-08-13 | $1.76M 10-Q · filed 2025-11-13 | $2.13M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $859.00K 10-Q · filed 2026-08-13 | $1.45M 10-Q · filed 2026-08-13 | $1.82M derived: sum of 3 quarters · filed 2026-08-13 | $2.27M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $587.00K 10-Q · filed 2026-05-15 | $957.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.41M derived: sum of 3 quarters · filed 2026-05-15 | $2.02M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $825.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.44M derived: sum of 3 quarters · filed 2026-03-27 | $2.12M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $455.00K 10-Q · filed 2025-11-13 | $1.07M derived: sum of 2 quarters · filed 2025-11-13 | $1.75M 10-Q · filed 2025-11-13 | $2.33M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $613.00K 10-Q · filed 2025-08-13 | $1.29M 10-Q · filed 2025-08-13 | $1.87M derived: sum of 3 quarters · filed 2025-08-13 | $2.46M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $678.00K 10-Q · filed 2025-05-13 | $1.26M derived: sum of 2 quarters · filed 2025-05-13 | $1.84M derived: sum of 3 quarters · filed 2025-05-13 | $2.55M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.17M derived: sum of 2 quarters · filed 2025-03-04 | $1.88M derived: sum of 3 quarters · filed 2025-03-04 | $3.35M 10-K · filed 2025-03-04 | $3.73M 10-K · filed 2024-03-21 |
| 2023-09-30 | $585.00K 10-Q · filed 2024-11-13 | $1.29M derived: sum of 2 quarters · filed 2024-11-13 | $2.77M 10-Q · filed 2024-11-13 | $5.18M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $708.00K 10-Q · filed 2024-08-13 | $2.19M 10-Q · filed 2024-08-13 | $4.60M derived: sum of 3 quarters · filed 2024-08-13 | $6.57M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $2.24M 10-Q · filed 2024-05-10 | $3.89M derived: sum of 2 quarters · filed 2024-05-10 | $5.86M derived: sum of 3 quarters · filed 2024-05-10 | $7.64M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $3.62M derived: sum of 2 quarters · filed 2024-03-21 | $5.40M derived: sum of 3 quarters · filed 2024-03-21 | $7.10M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $1.97M 10-Q · filed 2022-11-14 | $3.75M derived: sum of 2 quarters · filed 2022-11-14 | $5.46M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $1.77M 10-Q · filed 2022-08-12 | $3.48M 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | $1.71M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |